Lanean...

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

AIMS: Dapagliflozin is a sodium–glucose co‐transporter 2 inhibitor that has been developed as oral glucose lowering drug. The original dosefinding studies focused on optimal glycaemic effects. However, dapagliflozin also affects various cardiorenal risk markers and provides cardiorenal protection. T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Clin Pharmacol
Egile Nagusiak: Koomen, Jeroen V., Stevens, Jasper, Heerspink, Hiddo J.L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7576615/
https://ncbi.nlm.nih.gov/pubmed/32311110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14318
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!